VIB's Self-Sustaining Commercialization Ecosystem and Overcoming Funding Constraints

Amidst external financial crises caused by reduced research funding from the European Union (EU), the Flanders Bio-incubator (VIB), a non-profit biomolecular research institute in Belgium, is finding a way forward by building its own independent commercialization platform. Since its establishment in 1995, VIB has spun off 40 companies, attracting a cumulative 2 billion euros (approximately 2.28 billion U.S. dollars) in private investment, contributing to the delivery of research results to patients. This is considered an attempt to move away from the traditional European scientific research structure that relies on government research funding and to ensure the sustainability of the ecosystem by combining private capital and partnerships.

Overcoming Gram-Negative Bacteria with Precision Lysin Enzymes

VIB's core spin-off, Obulytix, is dedicated to developing precision lysin therapeutics (PLTs) to combat antimicrobial resistance (AMR). It utilizes AI to optimize lysins derived from bacteriophages, directly breaking down the cell walls of Acinetobacter baumannii, a bacterium that is difficult for existing drugs to penetrate. After successfully completing in vivo validation in mice, it secured 4 million euros (approximately 4.56 million U.S. dollars) from Boehringer Ingelheim, and is confident that this will become a unique therapeutic alternative in the future 9.8 billion U.S. dollar market for antimicrobial resistance treatments.

Securing a Global Big Deal Based on an AI Molecular Glue Platform

Spin-off Orionis Biosciences is leading the development of molecular glues that selectively disassemble disease-causing proteins, utilizing its unique Allo-Glue platform. With ORB-GX, a molecular glue pipeline currently in the IND-enabling stage, it has achieved significant success by signing technology transfer agreements with Novartis for up to 1.4 billion U.S. dollars and with Genentech for 2 billion U.S. dollars. This is a valuable virtuous business model in which an early-stage venture facing funding difficulties secures large-scale funding from global pharmaceutical companies (Big Pharma) to stabilize the development of novel drug pipelines.

Diversification into Agricultural Biotechnology and Local Ovarian Cancer Diagnostics

Rainbow Crops, a spin-off that combines genome editing and AI technology to develop climate-resistant crops, recently secured 9.7 million euros (approximately 11.25 million U.S. dollars) in seed funding. At the same time, VIB is localizing and distributing the Leuven HRD test, which identifies personalized treatments for ovarian cancer patients, at one-fifth the price of U.S. tests. In this way, the development of climate change-resistant food crops and the commercialization of low-cost precision diagnostics are becoming a strong support for overcoming government funding gaps and increasing local biomanufacturing capabilities in Europe.